President and Chief. Operating Officer shall be responsible for:
President and Chief. Executive Officer Each of the Selling Shareholders named in Schedule I hereto By ............................ Attorney-in-Fact By ...........................
President and Chief. Executive Officer -------------------------------------
President and Chief. Executive Officer Willxxx X. Xxxxx, Xx. ...............
President and Chief. Executive Officer of the Company, the Executive shall report only to the Board of Directors of the Company, and shall have powers and authority superior to those of any officer or employee of the Company or any subsidiary thereof.
President and Chief. Operating Officer of the Asset Management Division since December 1998. Xx. Xxxxx has been President and Director of MSDW Advisors since April 1997 and its Chief Executive Officer since June 1998. He was Executive Vice President and Chief Administrative Officer of Xxxx Xxxxxx Discover from 1994 until the Merger. He is President of approximately 100 registered investment companies for which MSDW Advisors serves as investment manager or investment adviser. He is also a trustee or director of approximately 25 registered investment companies for which Xxx Xxxxxx (or a subsidiary thereof) serves as investment manager or investment adviser. Name and Age Present Title and Principal Occupation ------------ --------------------------------------
President and Chief. Operating Officer of Discover Financial Services and Chairman of Discover Bank since September 1998. Xx. Xxxxx was a senior executive from 1992 until 1998 at MBNA America Bank where his last position was Vice Chairman. Xxxxxxx X. Xxxxxxxx, 53.. Co-President and Chief Operating Officer of MSDW's Institutional Securities Group since September 2000 and Chairman of Xxxxxx Xxxxxxx International Incorporated since January 2001. Xx. Xxxxxxxx was deputy head of MSDW's Institutional Securities Group from December 1997 until September 2000. Xx. Xxxxxxxx has been a Director and Vice Chairman of MS&Co. since December 1997 and a Managing Director of MS&Co. since 1988.
President and Chief. Executive Officer of XXXXXXXX said: “This agreement represents a major milestone for SCYNEXIS, maximising Brexafemme’s commercial potential in VVC and further validating our vision of the critical role for this first-in-class antifungal in invasive infections. We are thrilled to partner with GSK on this high-potential asset and will continue progressing ibrexafungerp’s phase III programme in invasive candidiasis (IC).” IC is a life-threatening infection that affects the blood or internal organs. There are around 750,000 cases of IC every year worldwide. In the US, it is one of the most common causes of bloodstream infections in hospitalised patients and can lead to more extended hospital stays and higher associated costs. Financial terms Under the terms of the agreement, GSK will make an upfront payment to SCYNEXIS of $90 million, plus additional potential milestone-based payments totalling $503 million. GSK will pay up to $245.5 million if specific development, regulatory, and commercial milestones associated with the IC indication are successfully completed. A further $15 million milestone will be paid upon successful US FDA approval of an additional indication. GSK will pay sales-related milestone payments based on achieving a certain commercial performance of up to $242.5 million, and mid-single digit to mid-teen digit tiered royalties on the totality of sales across all indications (in both cases with the top tier based on achieving net sales greater than $1 billion). GSK will also receive an exclusive licence to develop ibrexafungerp and commercialise Brexafemme in all countries except the greater China region and certain other countries already out-licensed by SCYNEXIS to third parties. Under the licence agreement, SCYNEXIS will continue executing the phase III programme for IC and other ongoing trials. SCYNEXIS retains rights to all other assets derived from enfumafungin. As part of this exclusive licence agreement, GSK has been granted a right of first negotiation to these compounds. This agreement is conditional upon customary conditions including review by the appropriate regulatory agencies under the Xxxx-Xxxxx-Xxxxxx Act. About Brexafemme (ibrexafungerp tablets) Brexafemme (ibrexafungerp tablets) is a novel oral glucan synthase inhibitor with a broad spectrum of activity including against emerging resistant threats. Its mechanism of action is similar to echinocandins, with fungicidal action against yeast (meaning it kills the fungus), versus f...
President and Chief. Executive Officer of Xxxxxxx Seating, Inc. From August 1996 to January 2000, he was Executive Vice President of Xxxxxxx Seating, Inc. Prior thereto, he held various positions with Bethlehem Steel Corporation.
President and Chief. Executive Officer I have read and accept this Agreement. By signing this Agreement, I represent and warrant to the Company that I am under no contractual commitments inconsistent with my obligations to the Company. Further, in consideration of my employment, I agree that, unless a shorter period of limitations applies, any claim, suit, action or other proceeding arising out of my employment or the termination of my employment, including but not limited to claims arising under state or federal civil rights statutes, must be brought or asserted by me within six (6) months of the event giving rise to the claim or be forever barred. I expressly waive any longer statute or other period of limitations to the contrary. Dated: , 2015 [EMPLOYEE NAME] PRONAI THERAPEUTICS, INC. OFFER LETTER - 10 EXHIBIT A Roles & Responsibility EXHIBIT B EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT AND NON-COMPETITION AGREEMENT THIS EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT AND NON-COMPETITION AGREEMENT (this “Agreement”) is made as of the date set forth below between PRONAI THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the undersigned employee of the Company (“Employee”). This Agreement confirms certain terms of Employee’s employment with the Company, which Employee acknowledges are a material part of the consideration for Employee’s employment by the Company, and the compensation received by Employee from the Company from time to time.
